Monitor the ozekibart BLA submission timeline and CTOS data presentation (Nov 19-20) for potential regulatory catalyst. The $199.5M cash position funds operations but debt service on $276.7M loan adds pressure; watch for financing needs if clinical milestones are delayed.
Drugs in focus
INBX drug pipeline →ozekibart
▲ Bullish Named in this press release- Impact
- Phase
- Filed/PDUFA (BLA accepted by FDA)
- Time to market
- PDUFA goal date is April14, 2027. If approved, launch could follow shortly after, positioning ozekibart as the first FDA-approved systemic therapy for conventional chondrosarcoma.
- Next catalyst
- PDUFA date · Apr 14, 2027 148d
What to watchThe next hard catalyst is the FDA PDUFA decision for ozekibart in conventional chondrosarcoma on April 14, 2027. An approval would make ozekibart the first FDA-approved systemic therapy for this rare bone cancer and likely drive a significant re-rating. A Complete Response Letter would be a severe setback given ozekibart is Inhibrx's lead asset. In the interim, watch the pace of sales under the newly filed $150M ATM equity offering and any updates on the accelerated approval pathway discussion for Ewing sarcoma.
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Inhibrx Biosciences reported Q3 2026 net loss of $38.7M ($2.46 per share), wider than the $35.3M loss in Q3 2025, with $2.0M in license fee revenue from Pfizer. The company highlighted upcoming clinical milestones for ozekibart in chondrosarcoma and Ewing sarcoma, and ordastobart in HNSCC and NSCLC, with cash of $199.5M funding operations into 2027.
Key Financial Metrics
Key Facts
- Net loss of $38.7M ($2.46 per share) vs $35.3M ($2.28) in Q3 2025
- Revenue of $2.0M from Pfizer license fee, vs $0 in Q3 2025
- Cash and equivalents $199.5M as of Sep 30, 2026, up from $124.2M at Dec 31, 2025
- R&D expense $26.0M, down from $28.5M; G&A $7.8M, up from $5.3M
- Long-term debt $276.7M, up from $100.6M at Dec 31, 2025
- Ozekibart (INBRX-109) BLA filing for chondrosarcoma advancing; updated Ewing sarcoma data at CTOS Nov 19-20
- Ordastobart (INBRX-106) HexAgon Phase 2 expansion in HNSCC enrolling; initial readout expected mid-2027
- Ordastobart Phase 1/2 in perioperative NSCLC results expected mid-2027
Financial Impact
Net loss of $38.7M, cash burn ~$38.7M per quarter; $199.5M cash provides runway into 2027
Risk Factors
- No approved products; pre-revenue biotech with ongoing clinical-stage losses
- High debt load ($276.7M) with increasing interest expense ($7.0M other expense vs $1.4M year ago)
- Clinical trial risks: Phase 2/3 data readouts not expected until mid-2027
- Dilution risk: potential need for additional capital given cash burn rate
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302939250 |
Track record
22 reports on INBX
2 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +29.54% at T+60 after the Jun 11, 2026 report. 6 of 12 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $80.43 Now $77.66 −3.44% settles Feb 12
- Nov 13, 20263d ago S-3ASR Bearish 5/10 Entry $82.85 Now $77.66 +6.26% settles Feb 12
- Nov 13, 20263d ago Press Release Neutral 4/10 Viewing Entry $83.30 Now $77.66 −6.77% settles Feb 12
- Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $73.29 Now $77.66 +5.96% settles Jan 26
- Oct 14, 20264w ago Insider Buy Bullish 4/10 Entry $90.50 Now $77.66 −14.19% settles Jan 12
- Sep 28, 20267w ago Insider Cluster Bullish 5/10 Entry $104.83 Now $77.66 −25.92% settles Dec 23
- Sep 17, 20268w ago Insider Cluster Bullish 5/10 Entry $109.35 Now $77.66 −28.98% settles Dec 14
- Sep 15, 20268w ago Insider Cluster Neutral 4/10 Entry $101.77 Now $77.66 −23.69% settles Dec 10
- Sep 15, 20268w ago 144 Neutral 2/10 Entry $101.77 Now $77.66 −23.69% settles Dec 10
- Sep 14, 20269w ago 144 Neutral 2/10 Entry $105.61 Now $77.66 −26.47% settles Dec 9
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers